Cancer Drug Parity Act of 2025
Sponsored By: Representative Grothman, Glenn [R-WI-6]
Introduced
Summary
Parity in cost-sharing for FDA‑approved oral anticancer medications. This bill would require group health plans to ensure cost-sharing for prescribed, patient‑administered oral anticancer drugs is no less favorable than cost-sharing for anticancer drugs given intravenously or by injection.
Show full summary
- Patients and families: Would make copayments, coinsurance, deductibles, and similar out-of-pocket limits for oral anticancer drugs at least as favorable as for IV or injected cancer treatments. This change applies to plan years beginning on or after January 1, 2026.
- Employers and insurers: Could not raise out-of-pocket costs, reclassify benefits to increase costs, or apply more restrictive limits to oral anticancer drugs to comply. Plans may still use prior authorization and other appropriate utilization controls consistent with existing law.
- Policymakers and researchers: Directs the Government Accountability Office to study the law's impact on out-of-pocket costs for covered group health plan enrollees and to report findings and recommendations within 2 years after enactment.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Equal costs for oral cancer pills in job-based plans
If enacted, job-based health plans would match cost-sharing for oral cancer pills to IV or injected chemo. This would apply only to FDA-approved, patient-administered drugs your doctor finds medically necessary or clinically appropriate. Plans could still use prior authorization, and stronger state protections would still apply. Plans could not raise out-of-pocket costs, reclassify benefits, or add tighter limits to dodge parity. The rule would start for plan years on or after January 1, 2026.
Sponsors & CoSponsors
Sponsor
Grothman, Glenn [R-WI-6]
WI • R
Cosponsors
Bonamici
OR • D
Sponsored 6/24/2025
Bilirakis
FL • R
Sponsored 6/24/2025
Rep. Fitzpatrick, Brian K. [R-PA-1]
PA • R
Sponsored 6/24/2025
Rep. Morelle, Joseph D. [D-NY-25]
NY • D
Sponsored 6/24/2025
Rep. Matsui, Doris O. [D-CA-7]
CA • D
Sponsored 6/24/2025
Rep. Brownley, Julia [D-CA-26]
CA • D
Sponsored 6/24/2025
Rep. Moore, Gwen [D-WI-4]
WI • D
Sponsored 6/24/2025
Davis (NC)
NC • D
Sponsored 6/24/2025
Rep. Davids, Sharice [D-KS-3]
KS • D
Sponsored 6/24/2025
Rep. Wilson, Joe [R-SC-2]
SC • R
Sponsored 6/24/2025
Kennedy (NY)
NY • D
Sponsored 6/25/2025
Rep. Castor, Kathy [D-FL-14]
FL • D
Sponsored 6/25/2025
Rep. Raskin, Jamie [D-MD-8]
MD • D
Sponsored 9/9/2025
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 9/15/2025
Rep. Balint, Becca [D-VT-At Large]
VT • D
Sponsored 9/15/2025
Bresnahan
PA • R
Sponsored 9/30/2025
Rep. Vindman, Eugene Simon [D-VA-7]
VA • D
Sponsored 10/3/2025
Rep. Ross, Deborah K. [D-NC-2]
NC • D
Sponsored 10/8/2025
Rep. Garamendi, John [D-CA-8]
CA • D
Sponsored 10/17/2025
Rep. Houlahan, Chrissy [D-PA-6]
PA • D
Sponsored 10/21/2025
Jackson (IL)
IL • D
Sponsored 10/24/2025
Conaway
NJ • D
Sponsored 11/7/2025
Rep. Salinas, Andrea [D-OR-6]
OR • D
Sponsored 11/7/2025
Rep. Bynum, Janelle S. [D-OR-5]
OR • D
Sponsored 11/7/2025
Rep. Neguse, Joe [D-CO-2]
CO • D
Sponsored 12/18/2025
Rep. Pappas, Chris [D-NH-1]
NH • D
Sponsored 12/18/2025
Schmidt
KS • R
Sponsored 3/16/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov